Intellia TherapeuticsNTLA
NTLA
About: Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Employees: 598
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
28% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 85
3% less funds holding
Funds holding: 287 [Q2] → 278 (-9) [Q3]
4.09% less ownership
Funds ownership: 95.8% [Q2] → 91.71% (-4.09%) [Q3]
8% less capital invested
Capital invested by funds: $2.07B [Q2] → $1.91B (-$155M) [Q3]
18% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 51
25% less funds holding in top 10
Funds holding in top 10: 4 [Q2] → 3 (-1) [Q3]
48% less call options, than puts
Call options by funds: $11M | Put options by funds: $20.9M
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
15%
upside
Avg. target
$49
299%
upside
High target
$91
647%
upside
9 analyst ratings
5 positive
56%
4 neutral
44%
0 negative
0%
Canaccord Genuity Whitney Ijem 21% 1-year accuracy 8 / 39 met price target | 639%upside $90 | Buy Maintained | 19 Nov 2024 |
Wells Fargo Yanan Zhu 6% 1-year accuracy 1 / 17 met price target | 475%upside $70 | Overweight Maintained | 18 Nov 2024 |
Wedbush David Nierengarten 38% 1-year accuracy 49 / 128 met price target | 15%upside $14 | Neutral Reiterated | 18 Nov 2024 |
Chardan Capital Geulah Livshits 17% 1-year accuracy 8 / 48 met price target | 647%upside $91 | Buy Maintained | 18 Nov 2024 |
Oppenheimer Jay Olson 20% 1-year accuracy 20 / 102 met price target | 393%upside $60 | Outperform Maintained | 11 Nov 2024 |
Financial journalist opinion
Based on 5 articles about NTLA published over the past 30 days
Negative
Zacks Investment Research
1 day ago
Intellia Crashes 60% in a Year: How Should You Play the Stock?
NTLA stock is down significantly in 2024 as investors are not pleased with the recent data from its in vivo CRISPR-based therapies. We advise prospective investors to stay on the sidelines for now.
Neutral
GlobeNewsWire
2 weeks ago
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on December 1, 2024, it awarded an inducement grant to one new employee under Intellia's 2024 Inducement Plan as a material inducement to employment.
Neutral
Zacks Investment Research
3 weeks ago
NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating hereditary transthyretin (ATTR) amyloidosis with polyneuropathy.
Neutral
GlobeNewsWire
3 weeks ago
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
CAMBRIDGE, Mass, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for the treatment of hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN). Nex-z is an in vivo CRISPR-based investigational therapy designed as a single-dose treatment to inactivate the TTR gene and thereby prevent the production of TTR protein for the treatment of ATTR amyloidosis. Development and commercialization of nex-z is led by Intellia as part of a multi-target collaboration with Regeneron.
Positive
The Motley Fool
4 weeks ago
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Neutral
Seeking Alpha
1 month ago
Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Intellia initiated the Phase 3 HAELO trial for NTLA-2002, targeting lifelong control of hereditary angioedema (HAE) with a single-dose CRISPR-based therapy. Positive Phase 2 NTLA-2002 data showed most patients remained attack-free; however, limitations like small sample size and short follow-up require cautious interpretation. Phase 1 data for nexiguran ziclumeran (nex-z) in ATTR amyloidosis showed disease stabilization, but competitive therapies demonstrate more robust improvements.
Neutral
GlobeNewsWire
1 month ago
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
CAMBRIDGE, Mass., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive new clinical data from the ongoing Phase 1 trial of nexiguran ziclumeran (nex-z, also known as NTLA-2001) in patients with transthyretin (ATTR) amyloidosis. Nex-z is an investigational in vivo CRISPR-based gene editing therapy in development as a one-time treatment for ATTR amyloidosis. Development and commercialization of nex-z is led by Intellia as part of a multi-target collaboration with Regeneron.
Positive
Seeking Alpha
1 month ago
Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus
Intellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on the Q3 earnings call setting the stage for a modest rally. While last month's drop is appropriately discounting NTLA-2002, investors should be encouraged that 3 Phase III trials will be engaged by year-end, representing multiple opportunities for substantial upside. Intellia's financial position is robust with $945 million in cash, enough to fund operations into late 2026.
Positive
MarketBeat
1 month ago
3 Fast-Growing Stocks Analysts See Doubling in Price
Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside potential at an opportune moment. Certainly, achieving this goal is easier said than done, and there is no guarantee that a company expected to make sizable gains will follow through on that promise.
Positive
Zacks Investment Research
1 month ago
NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus
Intellia's third-quarter earnings and revenues surpass estimates. The company provides updates on its pipeline candidates.
Charts implemented using Lightweight Charts™